Our early clinical trials programme consists of two phase I studies on healthy subjects and one phase Ib study on patients undergoing open-heart surgery.Read more
We are dedicated to developing tomorrow’s drugs against oxidative stress, helping millions of people to prevent and treat serious kidney diseases and get a better life. ROSgard, our biological drug candidate, mimics the body’s own most powerful and universal defense system against oxidative stress. Designed with a natural “homing” to the kidneys, ROSgard prevents experimental kidney damage by cleaning, protecting and repairing the exposed cells and tissues.
In 2019, A1M Pharma has streamlined the strategy with full focus on clinical development of the drug candidate ROSgard.
The first clinical study of ROSgard and dosing of the first subject started in April 2019. Approximately 35-40 healthy subjects will be recruited.
ROSgard is designed to mimic the body's own defence system against oxidative stress by protecting, cleaning and repairing exposed cells and tissue.